{"id":36171,"date":"2022-02-15T14:07:00","date_gmt":"2022-02-15T12:07:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&p=36171"},"modified":"2024-07-23T09:19:24","modified_gmt":"2024-07-23T07:19:24","slug":"cabometyx-in-combination-with-opdivo-demonstrated-continued-survival-and-quality-of-life-benefits-with-over-two-years-of-follow-up-in-the-phase-iii-checkmate-9er-trial","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/cabometyx-in-combination-with-opdivo-demonstrated-continued-survival-and-quality-of-life-benefits-with-over-two-years-of-follow-up-in-the-phase-iii-checkmate-9er-trial\/","title":{"rendered":"Cabometyx\u00ae in combination with Opdivo\u00ae demonstrated continued survival and quality of life benefits with over two years of follow-up in the Phase III CheckMate -9ER trial"},"content":{"rendered":"\n